Skip to main content

Primary Mitochondrial Diseases

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Minovia Therapeutics
Minovia TherapeuticsIsrael - Tirat Hacarmel
1 program
1
Bone Marrow mobilizationPhase 11 trial
Active Trials
NCT04548843Withdrawn0Est. Dec 2024

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
Minovia TherapeuticsBone Marrow mobilization

Clinical Trials (1)

NCT04548843Minovia TherapeuticsBone Marrow mobilization

A First in Human Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria) in Patients With Primary Mitochondrial Diseases Associated With Mitochondrial DNA Mutation or Deletion

Start: Mar 2022Est. completion: Dec 20240
Phase 1Withdrawn

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.